LEO Pharma Expands Dermatology Pipeline with 21 New Data Presentations
Event summary
- LEO Pharma to present 21 posters at the 2026 Fall Clinical Dermatology Conference, covering chronic hand eczema, generalized pustular psoriasis, atopic dermatitis, and pyoderma gangrenosum.
- New safety data from the Phase 3 DELTA TEEN trial for delgocitinib in adolescents with moderate to severe chronic hand eczema to be shared.
- Real-world effectiveness and safety outcomes of tralokinumab in atopic dermatitis from the non-interventional TRACE study to be presented.
- Long-term data and real-world use of spesolimab in generalized pustular psoriasis to be highlighted.
The big picture
LEO Pharma's extensive data presentations at the 2026 Fall Clinical Dermatology Conference underscore its commitment to advancing medical dermatology. The focus on chronic hand eczema, generalized pustular psoriasis, atopic dermatitis, and pyoderma gangrenosum aligns with the growing demand for targeted therapies in these areas. The company's strategic emphasis on real-world evidence and long-term data positions it to capture market share in a competitive dermatology landscape.
What we're watching
- Regulatory Approval
- Whether the FDA will approve delgocitinib for adolescents with moderate to severe chronic hand eczema based on the Phase 3 DELTA TEEN trial data.
- Market Positioning
- How LEO Pharma's expanded data on spesolimab and tralokinumab will position it against competitors in the dermatology space.
- Clinical Adoption
- The pace at which real-world evidence from the TRACE study will influence the adoption of tralokinumab in atopic dermatitis treatment.
Related topics